Supplementary Data Table T2 from Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies
In this study, we identified a threshold for “danger discrimination” in macrophages after sensing specific changes in protein expression at the surface of cells with an advanced premalignant phenotype
To better characterize the cellular pathways involved in breast cancer molecular subtypes, we performed a proteomic study using a label-free LC–MS strategy for determining the proteomic profile of Lum
Proteomics characterization of KAIMRC1 cell line, a naturally immortalized breast cancer cells, is described in comparison to MCF7 and MDA-231 breast cancer cells. Quantitative proteomics analysis usi
With the use of the breast cancer metastatic model, which comprises four isogenic cell lines, iTRAQ-based ESI-LC/MS/MS proteomics was employed to catalog protein expression changes as cancer cells acq